Jefferies Group LLC reaffirmed their buy rating on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a research note issued to investors on Friday morning. The brokerage currently has a $26.00 price objective on the biotechnology company’s stock.
A number of other research firms also recently weighed in on HRTX. Aegis restated a buy rating on shares of Heron Therapeutics in a research note on Tuesday, March 21st. Cantor Fitzgerald restated an overweight rating on shares of Heron Therapeutics in a research note on Monday, June 26th. Zacks Investment Research upgraded Heron Therapeutics from a hold rating to a buy rating and set a $14.00 price target on the stock in a research note on Wednesday, July 12th. Cowen and Company restated a buy rating and issued a $40.00 price target on shares of Heron Therapeutics in a research note on Friday, May 26th. Finally, ValuEngine upgraded Heron Therapeutics from a strong sell rating to a sell rating in a research note on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company. Heron Therapeutics currently has a consensus rating of Buy and a consensus target price of $31.89.
Shares of Heron Therapeutics (HRTX) traded up 4.85% on Friday, hitting $16.20. The stock had a trading volume of 1,717,997 shares. Heron Therapeutics has a one year low of $12.21 and a one year high of $24.00. The firm’s 50-day moving average is $14.19 and its 200-day moving average is $14.10.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.06. The company had revenue of $3.63 million during the quarter, compared to analysts’ expectations of $1.96 million. On average, analysts expect that Heron Therapeutics will post ($3.73) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.com-unik.info/2017/07/17/heron-therapeutics-nasdaqhrtx-buy-rating-reaffirmed-at-jefferies-group-llc.html.
In other news, VP Kimberly Manhard sold 21,542 shares of the business’s stock in a transaction on Monday, April 24th. The stock was sold at an average price of $15.33, for a total value of $330,238.86. Following the completion of the transaction, the vice president now directly owns 5,250 shares of the company’s stock, valued at $80,482.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 20.31% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in HRTX. State Street Corp boosted its position in Heron Therapeutics by 24.6% in the fourth quarter. State Street Corp now owns 1,367,565 shares of the biotechnology company’s stock worth $17,913,000 after buying an additional 270,022 shares during the period. Wells Fargo & Company MN boosted its position in Heron Therapeutics by 78.8% in the first quarter. Wells Fargo & Company MN now owns 39,579 shares of the biotechnology company’s stock worth $595,000 after buying an additional 17,442 shares during the period. FMR LLC boosted its position in Heron Therapeutics by 36.7% in the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock worth $120,464,000 after buying an additional 2,158,041 shares during the period. Point72 Asset Management L.P. bought a new position in Heron Therapeutics during the first quarter worth $2,002,000. Finally, Mesirow Financial Investment Management Equity Management bought a new position in Heron Therapeutics during the first quarter worth $435,000.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
What are top analysts saying about Heron Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heron Therapeutics Inc. and related companies.